Abstract:Background: Tuberculosis disease, caused by Mycobacterium tuberculosis, is a major public health problem. The emergence of M. tuberculosis strains resistant to existing treatments threatens to derail control efforts. Resistance is mainly conferred by mutations in genes coding for drug targets or converting enzymes, but our knowledge of these mutations is incomplete. Whole genome sequencing (WGS) is an increasingly common approach to rapidly characterize isolates and identify mutations predicting antimicrobial resistance and thereby providing a diagnostic tool to assist clinical decision making.Methods: We applied machine learning approaches to 16,688 M. tuberculosis isolates that have undergone WGS and laboratory drug-susceptibility testing (DST) across 14 antituberculosis drugs, with 22.5% of samples being multidrug resistant and 2.1% being extensively drug resistant. We used non-parametric classification-tree and gradient-boosted-tree models to predict drug resistance and uncover any associated novel putative mutations. We fitted separate models for each drug, with and without "co-occurrent resistance" markers known to be causing resistance to drugs other than the one of interest. Predictive performance was measured using sensitivity, specificity, and the area under the receiver operating characteristic curve, assuming DST results as the gold standard.Results: The predictive performance was highest for resistance to first-line drugs, amikacin, kanamycin, ciprofloxacin, moxifloxacin, and multidrug-resistant tuberculosis (area under the receiver operating characteristic curve above 96%), and lowest for third-line drugs such as D-cycloserine and Para-aminosalisylic acid (area under the curve below 85%). The inclusion of co-occurrent resistance markers led to improved performance for some drugs and superior results when compared to similar models in other large-scale studies, which had smaller sample sizes. Overall, the gradient-boosted-tree models performed better than the classification-tree models. The mutation-rank analysis detected no new single nucleotide polymorphisms linked to drug resistance. Discordance between DST and genotypically inferred resistance may be explained by DST errors, novel rare mutations, hetero-resistance, and nongenomic drivers such as efflux-pump upregulation.Conclusion: Our work demonstrates the utility of machine learning as a flexible approach to drug resistance prediction that is able to accommodate a much larger number of predictors and to summarize their predictive ability, thus assisting clinical decision making and single nucleotide polymorphism detection in an era of increasing WGS data generation.

The impact of machine learning on future tuberculosis drug discovery

Machine learning investigation of tuberculosis with medicine immunity impact

The past, present and future of tuberculosis treatment.

Leveraging large-scale Mycobacterium tuberculosis whole genome sequence data to characterise drug-resistant mutations using machine learning and statistical approaches

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Machine Learning Predicts Accurately Mycobacterium tuberculosis Drug Resistance From Whole Genome Sequencing Data

Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges

Evolution of Machine Learning in Tuberculosis Diagnosis: A Review of Deep Learning-Based Medical Applications

Identification of active molecules against Mycobacterium tuberculosis through machine learning

Exploring optimal drug targets through subtractive proteomics analysis and pangenomic insights for tailored drug design in tuberculosis

Development of new anti-tuberculosis drug candidates

From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning

Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape

Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment

Weak links: Advancing target‐based drug discovery by identifying the most vulnerable targets

Application of Computational Methods in Understanding Mutations in Mycobacterium tuberculosis Drug Resistance

25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward

Genetics-directed Drug Discovery for Combating Mycobacterium Tuberculosis Infection

Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Advancements in Artificial Intelligence for the Diagnosis of Multidrug Resistance and Extensively Drug-Resistant Tuberculosis: A Comprehensive Review

Recent Advancement in Predicting Subcellular Localization of Mycobacterial Protein with Machine Learning Methods